PHARMACEUTICAL MANAGEMENT OF PATIENTS WITH OBESITY USING GLP-1 ANALOGUES: A NARRATIVE REVIEW
DOI:
https://doi.org/10.51891/rease.v11i10.21522Keywords:
Tirzepatide. Clinical Evidence. Pharmaceutical Performance.Abstract
This article analyzed the use of GLP-1 analogs in the treatment of obesity, addressing their therapeutic indications, efficacy, mechanisms of action, adverse effects, and impact on patient quality of life. Furthermore, the study highlights the relevance of pharmaceutical interventions in light of the growing use of these medications, emphasizing the importance of multidisciplinary monitoring and specialized technical guidance to ensure treatment efficacy and safety. The methodology adopted consisted of a literature review of electronic databases (SciELO and PubMed), covering publications published between 2020 and 2025. Fifteen articles were selected after applying inclusion and exclusion criteria. Qualitative analysis of the evidence revealed consistent benefits of GLP-1 analogs, especially regarding weight loss and metabolic control. However, adverse events were also identified, reinforcing the need for rational use and continuous clinical monitoring.
Downloads
Downloads
Published
How to Cite
Issue
Section
Categories
License
Atribuição CC BY